Previous 10 | Next 10 |
Global Blood Therapeutics, Inc. ( GBT ) confirmed that the FDA has approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease in adults and children 12 years of age and older. According to the company press release , Oxbryta is the "first and only FDA-approved sickle hemo...
Global Blood Therapeutics (GBT) announced that it had received FDA approval for its drug Oxbryta (voxelotor) in treating adults and children ages 12 years and older with sickle cell disease ((SCD)). This is a good approval for the biotech, and it will be able to target a large market with it...
ChemoCentryx (NASDAQ: CCXI ) +323% on positive test results . More news on: ChemoCentryx, Inc., Nutanix, Inc., InflaRx N.V., Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the following investor conferences in December 2019: Evercore ISI 2 nd Annual HealthCONx Conference in Boston on Tuesday, December 3...
Global Blood Therapeutics (NASDAQ: GBT ) confirms that the FDA granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle cell disease in adults and children 12 years of age and older. More news on: Global Blood Therapeutics, Inc., Read more ...
First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older 1 Approval comes three months ahead of FDA’s priority review a...
On Nov. 15, the U.S. Food and Drug Administration (FDA) approved Adakveo (crizanlizumab) to treat painful episodes called vaso-occlusive crises in patients with sickle cell disease. Will this approval give Adakveo's manufacturer Novartis (NYSE: NVS) a big enough head start against Global Bl...
Global Blood Therapeutics (NASDAQ: GBT ): Q3 GAAP EPS of -$1.07 misses by $0.01 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third quarter ended September 30, 2019. “With the recent FDA acceptance of our NDA filing for vo...
Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further Establishes Relationship Between Higher Levels of Hemoglobin and Decreas...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...